Thought Leaders
Spray Drying Creates Faster-Dissolving CBD Powder

Key PointsSpray-dried CBD composite particles released more than 75% in roughly 20 to 25 minutes.
View more
- Spray-dried CBD composite particles released more than 75% in roughly 20 to 25 minutes.
- The 1% CBD loading means a 25 milligram dose would require 2.5 grams of powder.
- Droplet growth before drying makes processing time a critical product-quality variable.
Can changing the physical structure of CBD make it easier to formulate into useful oral products? The question matters because cannabidiol dissolves poorly in water. A product can contain a precisely measured amount of CBD while still presenting challenges for getting that ingredient into a form the body can absorb.
A study from TU Dortmund University, published online in the Journal of Pharmaceutical Innovation in November 2026, investigates one possible solution: forming tiny CBD-rich droplets and rapidly turning them into powder.1 The resulting material released CBD considerably faster in laboratory testing than crystalline CBD and two comparison formulations.
The findings offer a promising manufacturing direction. They also reveal why the next advance in oral CBD may depend on particle structure, processing time, and practical drug loading alongside the amount listed on a label.
Why CBD Dissolution Matters for Oral Products
Dissolution describes a substance entering solution. Bioavailability describes how much reaches the bloodstream. These are connected steps, but they measure different things: improving dissolution can address one obstacle without resolving everything that happens during digestion and metabolism.
For CBD, the challenge begins with its preference for oily environments over water. Researchers therefore investigate carriers and processing techniques that help CBD become available in watery surroundings. MyCannabis has explored this broader effort through its coverage of nanotechnology and CBD delivery.
One useful comparison is a sugar cube and the same amount of sugar broken into smaller pieces. Smaller pieces expose more surface to the surrounding liquid. CBD has different chemistry, but increasing accessible surface area can likewise help accelerate dissolution. The new study applies that principle within a powder designed for further pharmaceutical processing.
How Oiling Out Turns CBD Into Powder
The researchers started with CBD isolate and copovidone, a pharmaceutical polymer used as a carrier. They dissolved both in isopropanol, then mixed that solution with water.
Adding water changed the mixture’s ability to keep CBD dissolved. A separate liquid phase rich in CBD formed as tiny droplets. This phenomenon, called oiling out, supplied the small structures the researchers wanted to preserve.
They immediately fed the mixture into a spray dryer. The drying step removed liquid and embedded the CBD within larger composite particles. In principle, this combines the dissolution advantages of small CBD structures with powder particles that are easier to handle.
Timing proved important. The droplets grew when they remained in liquid before drying, so a delay could erode the advantage established during mixing. At the two-minute measurement, 90% of the droplets were smaller than 0.4 micrometers. Over 75 minutes, the characteristic droplet diameters roughly doubled.
Computer simulations helped compare two T-mixer configurations with a specially developed swirl mixer. The swirl design produced more uniform mixing and was selected for the experiments. This was fluid-flow modeling used to guide equipment design.
What the CBD Dissolution Tests Found
The team compared the composite powder with crystalline CBD, a physical mixture of CBD and carrier, and an amorphous solid dispersion. In the latter, CBD was distributed at the molecular level within the carrier, providing a more demanding benchmark than untreated CBD alone.
Testing used a circulating laboratory solution at 37°C containing water and 2% sodium lauryl sulfate, a surfactant that helps maintain dissolution conditions. The experiment measured release into that medium, without testing people or animals.
Those controlled conditions make comparisons between powders useful. They do not reproduce the changing environment of the digestive tract. The reported release percentages therefore describe performance in this test system; they cannot be read as the percentage of a swallowed dose that would enter someone’s bloodstream.
| Formulation | Reported Release | Study Context |
|---|---|---|
| Crystalline CBD | About 50% after 80 minutes | Untreated comparison powder |
| Physical mixture | About 75% after 85 minutes | CBD blended with copovidone |
| Amorphous solid dispersion | Slower than composite particles | Similar overall particle-size range |
| Composite particles | More than 75% in approximately 20 to 25 minutes | Oiling out followed by spray drying |
The composite particles had a median diameter of approximately 18 micrometers, within the range the authors targeted for further processing such as granulation or tableting. Their measured surface area also exceeded that of the amorphous comparison, which the researchers identified as another contributor to faster release.
There are consequently two size scales to keep separate: the tiny CBD-rich droplets formed before drying and the larger composite powder particles produced afterward. Preserving small structures inside a manageable carrier could help bridge the gap between favorable dissolution and the everyday demands of making a solid medicine.
Why Faster Dissolution Needs a Practical CBD Loading
The most consequential limitation is easy to overlook: the initial formulation experiments used only 1% CBD by weight. This helped the researchers examine the production approach while limiting complications associated with composition.
For a finished product, however, that percentage determines how much material someone would need to swallow. As an illustrative calculation, placing 25 milligrams of CBD in a powder containing 1% CBD requires 2.5 grams of powder. That is a manufacturing example, not a suggested dose or a product tested in the study.
Increasing the CBD loading could reduce that bulk, but developers would need to establish whether the rapid dissolution survives. The researchers observed oiling out at higher CBD proportions, including above 10%, which supports further investigation. It does not establish equivalent release performance at those higher loadings.
This creates a useful development target: maximize the amount of CBD carried by a manageable quantity of powder while preserving the structure responsible for its performance.
From a Fast Powder to a Reliable Manufacturing Process
The finding that droplets grow before drying makes processing time a product-quality variable. A larger factory cannot necessarily reproduce the result simply by moving more liquid through longer pipes. Developers would need to preserve the relevant mixing conditions and control the interval before drying.
That interpretation follows directly from the experiment, although industrial production was not demonstrated. Spray drying offers an established manufacturing platform; this particular CBD route still needs evidence on throughput, solvent removal, storage stability, and performance after conversion into a finished dosage form.
MyCannabis’s interview on pharmaceutical cannabinoid manufacturing provides related industry context on process controls and consistency. The scientific opportunity here is to connect a measurable powder property with a process that can reproduce it reliably.
What Human CBD Research Adds to the Picture
A separate 2026 human pharmacokinetic study compared a different powdered CBD formulation, CBtru, with the oil-based medicine Epidyolex in healthy adults under fed and fasted conditions.2 It reported comparable bioavailability with faster absorption for the powder formulation, while food substantially influenced CBD exposure.
That trial does not validate the Dortmund powder, which uses a different formulation. It does illustrate why human testing must examine the timing and variability of absorption as well as total exposure. A successful laboratory dissolution result supplies a reason to investigate those outcomes.
For readers comparing existing liquids, MyCannabis’s CBD oils and tinctures buying guide for Canada offers context on composition and batch documentation. Neither a high milligram count nor an advanced-delivery claim establishes how a particular product performs in people.
A potency test answers how much CBD a sample contains. A dissolution test examines its release under defined conditions. An absorption study measures what happens in the body. Keeping these questions separate makes genuine formulation progress easier to recognize.
The Next Questions for Solid Oral CBD
Three tests would make the manufacturing promise substantially more convincing:
- Repeat the dissolution advantage at higher CBD loadings.
- Confirm that storage and subsequent processing preserve performance.
- Measure absorption and variability in appropriately designed human studies.
The study identifies a controllable route to faster CBD release and explains why mixing and drying must work together. Its next important question is whether that advantage can survive the demands of a useful oral product: practical size, reproducible production, and predictable behavior after swallowing.
References:
1 Ercolin, E. M. A., Schulte, F., Schaldach, G., Bartsch, J., Kayser, O., & Thommes, M. (2027). Formulating cannabidiol (CBD) by oiling out and spray drying. Journal of Pharmaceutical Innovation, 22, Article 289. https://doi.org/10.1007/s12247-026-11153-1
2 Bendik, I., Beck, M., Manderna, A., Roos, F. F., Wang, J., McCarthy, D., Schweiggert, C., Besheer, A., Baisley, J., Misic, Z., Mussler, B., Kuttenkeuler, A., Piomelli, D., & Péter, S. (2026). Comparative pharmacokinetics and safety of cannabidiol in a powder formulation, CBtru®, vs an oil-based formulation, Epidyolex®, under fasted and fed conditions in healthy participants: A randomized open-label cross-over phase I study. CNS Drugs, 40(5), 709–723. https://doi.org/10.1007/s40263-026-01280-1












